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Introduction: The Universal Data Collection (UDC) Program of the Division of Blood Disorders at 
the Centers for Disease Control and Prevention (CDC) has initiated a pilot project at 9 U.S. 
Hemophilia Treatment Centers to perform post market surveillance for inhibitors. Goals are to 
prospectively collect risk factor and product exposure data, to provide centralized inhibitor 
monitoring, and to correlate inhibitor formation with genotype. 
Methods: Patients provide infusion logs with data on product brand, dose, and reason infused. A 
blood specimen is collected at baseline, annually, at product switch, or for clinical indication. Plasma 
and cells for DNA are shipped on cold packs to CDC, where inhibitor testing is done by the 
Nijmegen modification of the Bethesda assay, using commercially prepared buffered normal pooled 
plasma (BNPP) and deficient plasma from a hemophilic donor. A positive control with a known 
inhibitor titer is run with each assay. Specimens are screened for inhibitor at 3 parts patient plasma to 
1 part BNPP. Positive specimens are retested in dilutions. Results are reported in Nijmegen-Bethesda 
units (NBU). The intron 22 inversion of the FVIII gene is detected using a modified version of long-
range PCR. Utilizing the ABI 3730 Automated DNA sequencer, FVIII and FIX genes are sequenced 
in both directions, including both the 5' and 3' untranslated regions. 
Results: In the first year, 438 patients (80% hemophilia A) were enrolled. Comparison of 50 cold 
pack specimens to frozen specimens shipped on dry ice showed a correlation coefficient of 0.998. 
406 inhibitor tests have been performed. The effects of infused FVIII or FIX and heat treatment of 
specimens are being investigated. More than 200 gene analyses have been done. 
Conclusions: Centralized monitoring of inhibitors is feasible and promotes quality control. 
Concurrent mutation analysis will add to the data on risk factors. International coordination of such 
data collection will produce a powerful tool for surveillance. 
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